UNSPSC 51402002: Mebutamate

This classification denotes an antipsychotic agent with the molecular formula C10H20N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5H8F175RER, chemically known as 2,2-dicarbamyloxymethyl-3-methylpentane but generally known as mebutamate, which bears US NIH Compound Identifier 6151. European Medicines Agency schedules Mebutamate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08668MIG.

UNSPSC 51402002 Mebutamate is a Commodity code, but the recent state and local opportunities tagged under it reflect actual procurement of naloxone, safe drug deactivation systems, and generic multi-source pharmaceuticals and over-the-counter products rather than mebutamate specifically—indicating a significant mismatch between the code's nominal scope and what jurisdictions are actually buying. State and local governments soliciting under this code are acquiring emergency response medications, harm-reduction equipment, and pharmaceutical inventory to support public health initiatives, community health services, and pharmacy benefit programs. The issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, serving participating state and local government facilities across multiple states including Oregon). These solicitations span different procurement mechanisms—from traditional competitive bidding (IFB) for specific quantities of naloxone and deactivation systems, to market-intelligence gathering (RFI) for direct-to-manufacturer prescription programs, to cooperative purchasing vehicle RFPs for pharmaceutical product catalogs serving multi-state membership.

Recent activity appears concentrated in the South and Upper Midwest. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building, due July 26, 2023 (note: the posted and due dates suggest a data-entry error in the source). Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, as preliminary market research for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program. The Minnesota Department of Administration issued an MMCAP RFP on January 20, 2026 (S1070000015802) to establish multi-award contracts for generic pharmaceuticals and OTC products through authorized wholesalers, with proposals due March 26, 2026 and awarded vendors effective July 1, 2026. The code shows modest recent volume with a mix of issuing-body types but with no evident pattern of repeat activity or standout procurement concentration that would signal sustained demand.